180 related articles for article (PubMed ID: 26917951)
21. Analgesic effect of safinamide mesylate in a rat model of neuropathic pain.
Kogo Y; Koebis M; Kobayashi Y; Ishida T; Maeda T
Behav Brain Res; 2023 Aug; 452():114555. PubMed ID: 37355233
[TBL] [Abstract][Full Text] [Related]
22. The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study.
Rinaldi D; Bianchini E; Sforza M; Alborghetti M; Galli S; Salvetti M; Giovannelli M; Pontieri FE
Aging Clin Exp Res; 2021 Jun; 33(6):1689-1692. PubMed ID: 32681474
[TBL] [Abstract][Full Text] [Related]
23. Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review.
Sanchez Alonso P; De La Casa-Fages B; Alonso-Cánovas A; Martínez-Castrillo JC
Brain Sci; 2023 Feb; 13(2):. PubMed ID: 36831820
[TBL] [Abstract][Full Text] [Related]
24. Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
Gonzalez-Latapi P; Bhowmick SS; Saranza G; Fox SH
CNS Drugs; 2020 Oct; 34(10):1025-1044. PubMed ID: 32785890
[TBL] [Abstract][Full Text] [Related]
25. Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study.
Geroin C; Di Vico IA; Squintani G; Segatti A; Bovi T; Tinazzi M
J Neural Transm (Vienna); 2020 Aug; 127(8):1143-1152. PubMed ID: 32572581
[TBL] [Abstract][Full Text] [Related]
26. Fatigue in fluctuating Parkinson's disease patients: possible impact of safinamide.
Pauletti C; Locuratolo N; Mannarelli D; Maffucci A; Petritis A; Menini E; Fattapposta F
J Neural Transm (Vienna); 2023 Jul; 130(7):915-923. PubMed ID: 37210459
[TBL] [Abstract][Full Text] [Related]
27. Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.
Espinoza-Vinces C; Villino-Rodríguez R; Atorrasagasti-Villar A; Martí-Andrés G; Luquin MR
Patient Relat Outcome Meas; 2023; 14():285-295. PubMed ID: 37840836
[TBL] [Abstract][Full Text] [Related]
28. Green Spectrophotometric Platforms for Resolving Overlapped Spectral Signals of Recently Approved Antiparkinsonian Drug (Safinamide) in the Presence of Its Synthetic Precursor (4-Hydroxybenzaldehyde): Applying Ecological Appraisal and Comparative Statistical Studies.
El-Sayed HM; El-Abassy OM; Abdellatef HE; Hendawy HAM; Ibrahim H
J AOAC Int; 2022 Dec; 106(1):26-33. PubMed ID: 36214622
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of high doses of safinamide in advanced Parkinson disease.
Rodríguez-Jorge F; Beltrán-Corbellini Á; Chico-García JL; Parra-Díaz P; Baena-Álvarez B; Pagonabarraga J; Pérez-Torre P; Pareés I; López-Sendón JL; Martínez-Castrillo JC; Alonso-Cánovas A
Parkinsonism Relat Disord; 2022 Apr; 97():73-74. PubMed ID: 35344893
[No Abstract] [Full Text] [Related]
30. Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
Labandeira CM; Alonso Losada MG; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz González JM; Gonzalez Palmás MJ; Martínez Miró C; Santos García D
Adv Ther; 2021 Oct; 38(10):5398-5411. PubMed ID: 34523075
[TBL] [Abstract][Full Text] [Related]
31. Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice.
Pérez-Torre P; López-Sendón JL; Mañanes Barral V; Parees I; Fanjul-Arbós S; Monreal E; Alonso-Canovas A; Martínez Castrillo JC
Neurologia (Engl Ed); 2024 May; 39(4):340-344. PubMed ID: 38616061
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Safinamide and Gender Differences During Routine Clinical Practice.
Pellecchia MT; Picillo M; Russillo MC; De Pandis MF; Bonizzoni E; Marjanovic I; Cattaneo C
Front Neurol; 2021; 12():756304. PubMed ID: 34970207
[No Abstract] [Full Text] [Related]
33. Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A
Bhidayasiri R; Koebis M; Kamei T; Ishida T; Suzuki I; Cho JW; Wu SL
Front Neurol; 2023; 14():1147008. PubMed ID: 37051060
[TBL] [Abstract][Full Text] [Related]
34. Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence.
Müller T
J Exp Pharmacol; 2021; 13():397-408. PubMed ID: 33824605
[TBL] [Abstract][Full Text] [Related]
35. A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice.
Pagonabarraga J; Arbelo JM; Grandas F; Luquin MR; Martínez Martín P; Rodríguez-Oroz MC; Valldeoriola F; Kulisevsky J
Brain Sci; 2020 Mar; 10(3):. PubMed ID: 32197462
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review.
Sharaf J; Williams KD; Tariq M; Acharekar MV; Guerrero Saldivia SE; Unnikrishnan S; Chavarria YY; Akindele AO; Jalkh AP; Eastmond AK; Shetty C; Rizvi SMHA; Mohammed L
Cureus; 2022 Sep; 14(9):e29118. PubMed ID: 36259026
[TBL] [Abstract][Full Text] [Related]
37. Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey.
Takeda A; Tsuboi Y; Nomoto M; Mochizuki H; Hattori N
Parkinsons Dis; 2022; 2022():3203212. PubMed ID: 35873701
[TBL] [Abstract][Full Text] [Related]
38. Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.
Stocchi F; Antonini A; Berg D; Bergmans B; Jost W; Katzenschlager R; Kulisevsky J; Odin P; Valldeoriola F; Ray Chaudhuri K
NPJ Parkinsons Dis; 2022 Feb; 8(1):17. PubMed ID: 35190544
[TBL] [Abstract][Full Text] [Related]
39. Pemphigoid-like Skin Lesions Following Introduction of Safinamide.
Lachance L; Huot P
Can J Neurol Sci; 2023 Jul; 50(4):647-648. PubMed ID: 35695178
[No Abstract] [Full Text] [Related]
40. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R
JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
